The transition of spinal cord NSCs from quiescent to proliferative cells is associated with changes in the microenvironment after SCI. Previous report shows vascular integrity improves neuroregeneration, implying the important roles of vascular in neuroregeneration. 7, 8 In adults, NSCs are located near vascular endothelial cells that provide oxygen to neural cells, and proliferate in small clusters around dividing capillaries in the CNS. 9 After injury, events such as hypoxic conditions, cytokine, and growth factor secretion contribute to NSCs proliferation. 10 Vascular endothelial growth factor A (VEGF-A, VEGF in short), a member of VEGF family and first identified as a regulator of angiogenesis, can be easily induced by hypoxic conditions. 11 In the nervous system, VEGF exerts a protective effect on neurons and promotes neurite extension in spinal cord explants, possibly by stabilizing and upregulating MAP2 (microtubule-associated protein 2) expression. 12 Importantly, VEGF has mitotic effects on NSCs through interactions with VEGF receptors (VEGFRs) and enhances neurogenesis in the hippocampus, [13] [14] [15] whereas NSCsspecific loss of VEGF results in impaired stem cell maintenance. 16 Furthermore, VEGF is upregulated following CNS injury.
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Nevertheless, very little is known about the contribution of VEGF to spinal cord NSCs activation following SCI.
Epidermal growth factor receptor (EGFR, also known as ErbB1)
was the first identified receptor of the ErbB family. Currently, the ErbB family includes EGFR, ErbB2, ErbB3, and ErbB4. EGFR can be transactivated by several signaling molecules, including G-protein-coupled receptor (GPCR)-mediated signaling, protein kinase C (PKC), and nonreceptor tyrosine kinases such as Src and Pyk2.
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In the nervous system, EGFR signaling promotes the proliferation and survival of NSCs and inhibits neuronal differentiation. [23] [24] [25] In particular, EGFR interacts with some pathways to promote NSCs proliferation in vivo. 26, 27 Notably, EGFR expression is upregulated under hypoxic conditions generated by spinal or peripheral nervous injury. 28, 29 Here, we demonstrate that VEGF promotes spinal cord NSCs activation through EGFR transactivation following SCI. Our results reveal that VEGF may act as a driving force for NSCs activation, and provide new insights into the mechanisms of NSCs activation following SCI.
| MATERIAL S AND ME THODS

| Animals and ethics statement
Female Sprague Dawley (SD) rats (210-230 g) were purchased from Vital River (China) and housed in temperature-controlled (24°C) and humidity-controlled (50%) animal quarters with a 12-hour light/dark cycle with free access to food and water. All animal experiments
were performed in accordance with the Chinese Ministry of Public Health Guide and US National Institutes of Health Guide for the care and use of laboratory animals. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
| Animal surgery models
Surgeries were performed under strict sterile conditions.
Female adult SD rats (210-230 g) were used for surgery. Animals were anesthetized by intraperitoneal (ip) injection of chloral hydrate (0.5 g/kg) before surgery according to previous protocol. 30 Two surgical models were used: (1) complete spinal cord injury between thoracic 8 and 9 (T8-T9); (2) intraspinal injection.
1.
For complete spinal cord injury, the pelage on the back of the anesthetized rat was shaved, and the skin was cleaned with povidone iodine solution. A 2-mm-long gap was made between T8 and T9 of the spinal cord. Absorbable gelatin sponge (Xiang En) was used to control bleeding at the transection site. The rat survival rate after injury was above 80%. 
| Experimental groups and treatment
1.
Complete spinal cord injury between T8 and T9 (n = 35; 5 rats/group) was divided into seven groups: 0, 1, 3, 7 days postinjury, respectively; SCI group (as control), gefitinib group, and cabozantinib group.
Animals of gefitinib group and cabozantinib group were administrated with inhibitors, respectively, by intraperitoneal injection for a week before surgery (75 mg/kg, dissolved in 0.5% DMSO; 0.5% DMSO injection as control), and administration continued throughout the experiments. The 0-day postinjury (0 dpi) group represents a model without spinal cord injury, but with a laminectomy.
2.
Intraspinal injection (n = 30; 5 rats/group) was divided into six groups: control group; VEGF group; gefitinib group; cabozantinib group; VEGF + gefitinib group; VEGF + cabozantinib group.
Animals of inhibitors-treated groups were administrated with two specific inhibitors (gefitinib and cabozantinib), respectively, by intraperitoneal injection for a week before surgery (75 mg/kg, dissolved in 0.5% DMSO; 0.5% DMSO injection as control), and administration continued throughout the experiments. Intraspinal injections into the spinal cord were performed using a 25-G needle loaded with different factors (inhibitors: 75 mg/kg; VEGF: 500 ng/rat) at 45° to the spinal cord.
Each day the bladders of animals were squeezed to extrude urine twice and the animals were injected with penicillin/streptomycin once, with free access to food and water.
| Tissue preparation
Spinal cord tissue was collected from around the injury site
(1 cm) after cardiac puncture and fixed with 4% PFA (paraformaldehyde) overnight for immunofluorescence. Tissue was then dehydrated in 30% sucrose for 2 days. Cryosections (20 µm) were taken and used for immunofluorescence studies by incubating the sections overnight with primary antibodies before labeling with Alexa Fluor-conjugated secondary antibodies. All of the samples were used for assays, and every experiment was repeated three times.
| Spinal cord NSCs culture
Spinal cord NSCs were isolated from the spinal cord of postnatal 
| Differentiation of spinal cord NSCs
Spinal cord NSCs spheres were cultured for 7 days and dissoci- (Beyotime, Shanghai, China) was added to each well, and the cells were cultured at 37°C in 5% CO 2 for 4 hours. VEGF-containing medium with no cells was used as a blank. After 4 hours, the plates were shaken for 1 minute to mix the solutions before detection.
| Cell viability assay
The plates were read at 450 nm (420-480 nm), and the reference wavelength was 690 nm.
| Immunofluorescence
Cells were fixed with 4% PFA for 30 minutes at room temperature (RT), treated with 0.3% Triton X-100 for 10 minutes, and blocked for Supplementary Table S1 .
| Western blotting
Cells or spinal cord tissue was lysed into RIPA lysis (with pro- Supplementary Table S1 . 
| Calcium imaging
| Statistical analysis
Two-tailed unpaired Student's tests were used to test the comparisons between two groups. All error bars represent mean ± SEM. The significance level was set at P ≤ 0.05 (exact P values, see figure legends). All experiments were repeated three times.
| RE SULTS
| Spinal cord NSCs activation is accompanied by elevated VEGF expression after SCI
In the intact spinal cord, NSCs are confined within the ependymal cell population and remain quiescent, and the expression of nestin is restricted. 31 Our previous study shows that spinal cord NSCs are activated and proliferate robustly after SCI, using nestin immunofluorescence to represent NSCs. 32 We performed severe T8-T9 SCI rat models (n = 5 rats/group) and observed the nestin-positive NSCs around the injury sites were significantly elevated from day 1, peaked on day 3 postinjury, and subsequently decreased on day 7 postinjury (Figure 1A ), which suggests that 1 dpi (days postinjury) is when NSCs activation occurs earlier after SCI. Destruction of the vascular system was the earliest event after SCI, subsequently generating a hypoxic condition, which may contribute to spinal cord NSCs activation after injury. 33 In our study, we found that Hif 1α expression, which was induced by hypoxia and has been shown to promote VEGF expression, was increased around the injured region after 3 days postinjury (n = 2; Supplementary Figure S1 ). Furthermore, we found that VEGF had a similar expression pattern to nestin ( Figure 1B ). In addition, the evaluation of protein levels of nestin and VEGF around the injured regions further confirmed that both NSCs activation and VEGF expression were elevated on day 3 post-SCI ( Figure 1C ). These results imply that the elevated VEGF expression may play a role in the activation of endogenous spinal cord NSCs after SCI.
| VEGF promotes the proliferation of spinal cord NSCs in vitro
The elevation of VEGF expression accompanied by NSCs activation after SCI indicates that VEGF may exert mitotic effects on Spinal cord tissue cells were cultured in suspension with different concentrations of VEGF: 0 ng/mL (as a control), 20, 50, and 100 ng/mL. As expected, several cellular aggregates were seen on day 1 (data not shown), and these had grown into neurospheres by days 3 and 5, with increasing diameters (Figure 2A) . We meas- We further identified that the cells in the spinal cord-derived neurospheres induced by VEGF had NSCs identities. As the secondary sphere reformation assay is usually used to identify NSCs, we dissociated the neurospheres into single cells and continued to culture them in suspension for 5 days. The observation that the secondary spheres presented larger diameters with increasing VEGF concentrations might be because the secondary spheres were more proliferative ( Figure 3A,B) . As 100 ng/mL VEGF was able to induce
NSCs proliferation more robustly than 20 and 50 ng/mL, we performed subsequent experiments using 100 ng/mL VEGF. Next, we In addition, cells derived from the VEGF-cultured spheres could also differentiate into Tuj1 + neurons and GFAP + astrocytes, in accordance with the differentiation potential of NSCs ( Figure 3E ). VEGF could therefore serve as a growth factor to induce spinal cord NSCs proliferation in vitro.
| Transactivation of EGFR by VEGF promotes the proliferation of spinal cord NSCs
EGFR is a type of RTK, and it plays an important role in cell proliferation. In the hippocampus, EGFR is extensively expressed in TAPs (transit-amplifying precursors), which are considered the most rapidly proliferating cells in the brain. 36 Previous studies have shown that EGFR immunoreactivity is increased following ischemia caused by brain injury. 37 In our study, we found that EGFR phosphorylation in injured spinal cord tissue was also elevated after SCI (Supplementary Figure S2) . We speculated that VEGF could interact with EGFR to promote spinal cord NSCs proliferation. To verify this hypothesis, we first assessed the expression of EGFR in spinal cord NSCs in vitro.
The dissociated NSCs were seeded on cover slips precoated with F I G U R E 3 VEGF-induced spinal cord-derived neurospheres have self-renewal ability and differentiation potential similar to NSCs. A, Neurospheres cultured for 5 d can form secondary spheres after being passaged in the presence of VEGF. Scale bar represents 100 µm. B, Average diameters of secondary spheres. VEGF 100 ng/mL shows the most proliferation compared with control (P = 0.0011). *P ≤ 0.05 and **P ≤ 0.01. Control, 0 ng/mL VEGF. C and D, Neurospheres induced by VEGF express NSCs markers. Nestin (green); BLBP (red); vimentin (red). Scale bar represents 200 µm. E, Neurospheres induced by VEGF differentiate into Tuj1 + neurons (green) and GFAP + astrocytes (green).
Scale bar represents 100 µm. EGF + FGF group is used as the positive control in (C-E) PLL (poly-l-lysine) and starved for 3 days in serum-free medium to inhibit the in-house phosphorylation of EGFR (pEGFR). On day 4, we checked whether VEGF could stimulate EGFR phosphorylation, with 20 ng/mL EGF as the positive control. Immunofluorescence showed that spinal cord NSCs expressed EGFR, and EGFR could be activated into pEGFR by VEGF or EGF, 10 minutes for stimulation ( Figure 4A ).
Next, using western blotting, we further confirmed that VEGF could induce EGFR phosphorylation ( Figure 4B) . We employed the pEGFRspecific inhibitor gefitinib (ZD1839, 1 µM) to efficiently block EGFR phosphorylation at tyrosine residues. Western blotting showed that VEGF increased pEGFR levels, whereas gefitinib inhibited this effect, even in the presence of VEGF ( Figure 4C ). These results confirmed that VEGF could activate the phosphorylation of EGFR in spinal cord
NSCs. Next, we characterized the effects of gefitinib on spinal cord
NSCs proliferation. Compared with the VEGF group, the spheres exhibited growth arrest and reduced average diameters in the presence of gefitinib or combined with VEGF ( Figure 4D,E) . These results suggest that pEGFR induced by VEGF is essential for the proliferation of spinal cord NSCs.
| VEGF transactivates the EGFR signal through VEGFR2
VEGF has two receptors, VEGFR1 and VEGFR2. First, we determined the expression of VEGFRs in spinal cord NSCs. Our results
showed that spinal cord NSCs expressed VEGFR2 but not VEGFR1, and that VEGFR2 could be activated when VEGF was added in vitro ( Figure 5A ). In vivo results further validate the expression of VEGFR2, but not VEGFR1 in central canal and VEGFR2 could also be phosphorylated after injury (Supplementary Figure S3) . We postulated that VEGF could activate EGFR through VEGFR2. As expected, both 20 and 100 ng/mL VEGF could activate VEGFR2
and phosphorylate EGFR ( Figure 5B ). When the VEGFR2-specific inhibitor cabozantinib (XL184, 1 µM) was added in our system, we found that the phosphorylation of both VEGFR2 and EGFR was inhibited ( Figure 5C ). The growth of spinal cord NSCs was also inhibited by cabozantinib ( Figure 5D ). Additionally, western blotting results showed that EGFR phosphorylation was blocked under the inhibitor gefitinib; however, phosphorylation of VEGFR2 was not in- Figure S6) . These results indicate that the transactivation of EGFR by VEGF is likely mediated by calcium signaling.
| VEGF activates spinal cord NSCs by VEGFR2-EGFR signaling in vivo
To test the effects of VEGF on spinal cord NSCs in vivo, we injected VEGF into the rat spinal cord (at the same site as the previously described injections, n = 30) using a 25-G needle at 45° to the spinal cord ( Figure 6A ). The proliferative effects of VEGF may be concealed by robust NSCs activation after SCI. Here, we performed injection model because injection induced less NSCs activation than SCI. On day 3 after the injection, we found that the VEGF injection group had a higher number of activated NSCs (nestin We demonstrated that VEGFR2-EGFR signaling is important for the activation of spinal cord NSCs; therefore, we aimed to investigate its effects on NSCs activation after severe SCI. We found that, after severe SCI, intraspinal injection of gefitinib and cabozantinib under our routine differentiation protocol, because some additional essential supplements should be added to the medium to induce oligodendrocyte differentiation. 40 In vivo, VEGF injection into the spinal cord activated NSCs, whereas inhibitors of VEGFR2 decreased NSCs activation after SCI.
| D ISCUSS I ON
In all, our results illustrate that hypoxia and VEGF may act as driving force of NSCs activation after injury, at least to some extent.
| VEGF activates EGFR signal through VEGFR2
Our results showed VEGF activated EGFR signal through VEGFR2.
Primarily we supposed that VEGF promoted the expression and secretion of EGF (epidermal growth factor) to activate EGFR. We cul- 
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